Ask AI

A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?

Enhance your knowledge of current and emerging menin inhibitors and the clinical rationale for inhibiting menin in the treatment of AML based on the latest evidence and expert recommendations through an audio podcast, expert-authored ClinicalThought commentary, and certified text module with accompanying downloadable slides.

Share

Program Content

Activities

Menin Inhibitors in AML
A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: July 25, 2025

Expires: January 24, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Kura Oncology, Inc. and Syndax Pharmaceuticals, Inc.

Kura Oncology, Inc.

Syndax Pharmaceuticals, Inc.